DENVER – Each year, 13 percent of all newly diagnosed lung cancer patients are diagnosed with small-cell lung cancer (SCLC).
DENVER – ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer (
Study supports continued research on specific treatment for women with lung cancer who are never-smokers
DENVER – The incidence of lung cancer in women affects an estimated 516,000 women worldwide, of which 100,000 are in the United States and 70,000 i
DENVER – The implementation of personalized health care in cancer relies on the identification and characterization of cancer biomarkers and the av
DENVER – Stereotactic body radiotherapy (SBRT) is considered the treatment of choice for early-stage non–small-cell lung cancer (NSCLC) if patients
DENVER – Personalized medicine in lung cancer relies on the identification and characterization of cancer biomarkers and the availability of accura